Beware Sudden Osteoporosis (Forteo "Junk Bone" Merged Topic)

[annapurna]

I believe that the bone necrosis was more a historical concern, leading me to believe that it was more due to earlier anti-osteoporosis meds that limited bone resorption rather than increased bone creation like Forteo does. I've not studied this very much but the concern has been around for a while and earlier meds did limited the resorption of old bone. Does anyone know of a study that links Forteo with necrosis?

[Harrison]

I believe I posted this in the "warnings" section a while back...

Popular Osteoporosis Drugs Triple Risk Of Painful Bone Necrosis, Study Finds

ScienceDaily (Jan. 15, 2008) — A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain.

"...The epidemiological study, a collaboration between UBC, VCHRI and McGill University, is based on the health records of 88,000 Quebec residents from 1996 to 2003. The team undertook the research after academic papers began linking necrosis of the jaw with the use of bisphosphonates...."

http://www.sciencedaily.com/releases...0115092048.htm

[Harrison]

Here are a few more links…
_____________________________________________

Public Citizen issues warning against Forteo
OB/GYN News, May 15, 2003 by Kate Johnson
http://findarticles.com/p/articles/mi_m0CYD/is_10_38/ai_102340267/

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta (OI)
Verified by Oregon Health and Science University, February 2009
http://clinicaltrials.gov/ct2/show/NCT00131469

Microbial Biofilms in Osteomyelitis of the Jaw and Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy

P.P. Sedghizadeh, S.K.S. Kumar, A. Gorur, C. Schaudinn, C.F. Shuler, J.W. Costerton
http://jada.ada.org/cgi/content/abstract/140/10/1259

Dr. Sedghizadeh and colleagues report their observations of microbial biofilms in osteomyelitis of the jaw, compare these findings with those pertaining to osteonecrosis of the jaw and discuss recent findings that the pathogenesis of osteonecrosis of the jaw may represent a biofilm-mediated infectious disease in the context of bisphosphonate therapy.

By the way, Forteo is not classified as a biphosphonate. A good overview with some reference links (previously posted elsewhere on this site is here):

Current Controversies in Bisphosphonate Therapy
http://www.orthosupersite.com/view.asp?rID=41200

Forteo mfr spec sheet (Lilly France) Attached to this post and here:
http://pi.lilly.com/us/forteo-pi.pdf

Jim/Laura: If you dig into the data sheet, you may find page 8 interesting:

Phosphorus and Vitamin D

— In single-dose studies, teriparatide produced transient phosphaturia and mild transient reductions in serum phosphorus concentration. However, hypophosphatemia (<0.74 mmol/L or 2.4 mg/dL) was not observed in clinical trials with FORTEO.

In clinical trials of daily FORTEO, the median serum concentration of 1,25-dihydroxyvitamin D was increased at 12 months by 19% in women and 14% in men, compared with baseline. In the placebo group, this concentration decreased by 2% in women and increased by 5% in men. The median serum 25-hydroxyvitamin D concentration at 12 months was decreased by 19% in women and 10% in men compared with baseline. In the placebo group, this concentration was unchanged in women and increased by 1% in men.

[ans]

Dear Harrison,

Thank you so much for providing these links to something I w/never understand. I truly am appreciative Richard.

Wishing you my best. - Allan